Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study

被引：0

作者：

Corren, J. ^{[1
]}

Garcia Gil, E. ^{[2
]}

Parnes, J. R. ^{[3
]}

Pham, T. ^{[4
]}

Griffiths, J. M. ^{[4
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] AstraZeneca, Barcelona, Spain

[3] Amgen Inc, Thousand Oaks, CA 91320 USA

[4] MedImmune, Gaithersburg, MD USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A2621

引用

收藏

页数：2

相关论文

共 2 条

[1] Tezepelumab in Adults with Uncontrolled Asthma
Corren, Jonathan
Parnes, Jane R.
Wang, Liangwei
Mo, May
Roseti, Stephanie L.
Griffiths, Janet M.
van der Merwe, Rene
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (10) : 936 - 946
[2] Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, Gail M.
O'Byrne, Paul M.
Boulet, Louis-Philippe
Wang, Ying
Cockcroft, Donald
Bigler, Jeannette
FitzGerald, J. Mark
Boedigheimer, Michael
Davis, Beth E.
Dias, Clapton
Gorski, Kevin S.
Smith, Lynn
Bautista, Edgar
Comeau, Michael R.
Leigh, Richard
Parnes, Jane R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) : 2102 - 2110